Effect of Shenqi Yiliu Prescription Combined with Cisplatin on Tumor in Hepatoma H22-bearing Mice Based on PTEN/PI3K/Akt Signaling Pathway
10.13422/j.cnki.syfjx.20221721
- VernacularTitle:基于PTEN/PI3K/Akt信号通路探讨参芪抑瘤方联合顺铂对H22肝癌荷瘤小鼠的抑瘤作用
- Author:
Xin FENG
1
;
Yongqiang DUAN
2
;
Min BAI
1
;
Yuping YANG
1
;
Liren CAO
1
;
Junrui HU
2
;
Yanhua SI
2
;
Jing CHEN
2
;
Zihan GONG
3
;
Lan MA
4
Author Information
1. Gansu University of Chinese Medicine， Lanzhou 730000， China
2. College of Traditional Chinese Medicine （TCM）， Ningxia Medical University， Yinchuan 750004， China
3. Institute of Basic Theory of TCM， China Academy of Chinese Medical Sciences， Beijing 100700， China
4. General Hospital of Ningxia Medical University， Yinchuan 750004， China
- Publication Type:Journal Article
- Keywords:
Shenqi Yiliu prescription;
cisplatin;
phosphatase and tensin homolog deleted on chromosome ten （PTEN）/phosphatidylinositol3-kinase （PI3K）/protein kinase B （Akt） signaling pathway;
proliferation
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2023;29(3):96-103
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the tumor-suppressing effect of Shenqi Yiliu prescription combined with cisplatin in hepatoma H22-bearing mice based on the phosphatase and tensin homolog deleted on chromosome ten （PTEN）/phosphatidylinositol-3-kinase （PI3K）/protein kinase B （Akt） pathway. MethodH22-bearing mice were prepared and randomized into model group， cisplatin group， and cisplatin combined with high-， medium-， and low-dose Shenqi Yiliu prescription groups， with 10 mice in each group. Another 10 healthy mice were randomly selected as normal group. Shenqi Yiliu prescription was given by gavage with the high， medium， low dose of 54.06， 27.03， 13.515 g·kg-1·d-1， respectively， and cisplatin （2.5 mg·kg-1） was administered by intraperitoneal injection， twice a week. Normal group and model group received normal saline. After 13 days of treatment， mice were killed and the tumor inhibition rate was calculated. The pathomorphological changes of tumor were observed based on hematoxylin-eosin （HE） staining， and enzyme-linked immunosorbent assay （ELISA） and immunofluorescence method were used to detect the content of cyclin-dependent kinase inhibitor 1A （p21） and cyclin-dependent kinase inhibitor 1B （p27） in tumor tissue of mice. The levels of PTEN， PI3K and phosphorylated protein kinase B （p-Akt） in tumor tissue were measured by Western blot. ResultCompared with the model group， cisplatin alone and cisplatin in combination with the high-， medium-， and low-dose Shenqi Yiliu prescription decreased tumor mass （P<0.05）， particularly the cisplatin in combination with the high-dose Shenqi Yiliu prescription. Necrosis of the tumor tissue was observed in each group， especially the cisplatin combined with high-dose Shenqi Yiliu prescription group. As compared with the model group， cisplatin alone and cisplatin in combination with the high-， medium-， and low-dose Shenqi Yiliu prescription raised the expression of p21， p27， and PTEN （P<0.05） and lowered the expression of PI3K and p-Akt （P<0.05）， particularly the cisplatin in combination with high-dose Shenqi Yiliu prescription. ConclusionShenqi Yiliu prescription may regulate the expression of key molecules in PTEN/PI3K/Akt signaling pathway， thereby upregulating the expression of downstream proliferation inhibitors p21 and p27， further suppressing the tumor in H22-bearing mice， and enhancing the effect of chemotherapy.
